ロード中...
Delaying Chemotherapy in the Treatment of Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
Global guidelines for the management of locally advanced or metastatic hormone receptor–positive (HR-positive), human epidermal growth factor 2–negative (HER2-negative) breast cancer recommend endocrine therapy as first-line treatment for all patients, regardless of age or postmenopausal status. How...
保存先:
| 出版年: | Clin Med Insights Oncol |
|---|---|
| 第一著者: | |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Libertas Academica
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4697769/ https://ncbi.nlm.nih.gov/pubmed/26793013 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4137/CMO.S31586 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|